Cognitive training program for survivors of hematopoietic cell transplantation
Intervention Strategies to Improve Cognitive Functioning in Hematologic Cancer Survivors After Hematopoietic Cell Transplantation
This study is testing a brain training program to see if it can help people who have survived hematopoietic cell transplantation think better and improve their memory over 12 weeks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Trial ID | NCT03094026 on ClinicalTrials.gov |
What this trial studies
This pilot study evaluates the feasibility of enrolling patients in a cognitive training intervention aimed at improving neurocognitive function in survivors of hematopoietic cell transplantation (HCT). Participants will use the Lumosity online cognitive training program, which includes various tasks designed to enhance processing speed, working memory, and executive function over a 12-week period. Additionally, the study will assess patients' interest in receiving genetic risk information related to cognitive impairment following HCT, exploring their attitudes towards genetic knowledge and its potential impact on treatment decisions.
Who should consider this trial
Good fit: Ideal candidates are English-speaking adults aged 21 and older who are outpatient survivors of allogeneic HCT performed at UAB, between 3 and 6 months post-transplant.
Not a fit: Patients with pre-existing neurological disorders, major psychiatric disorders, or significant sensory impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could enhance cognitive function in HCT survivors and improve their quality of life.
How similar studies have performed: While cognitive training interventions have been explored in various populations, this specific approach targeting HCT survivors is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 21 years old at time of allogeneic HCT performed at UAB * Outpatient and between 3 and 6 months post HCT * English speaking * Possess access to an internet-connected home computer Exclusion criteria: * History of pre-existing neurological disorder or documented major psychiatric disorder; significant auditory, visual, or motor impairments * Participated in neuropsychological intervention within the past 6 months * History of color blindness
Where this trial is running
Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama, United States (Recruiting)
Study contacts
- Principal investigator: Noha M Sharafeldin — University of Alabama at Birmingham
- Study coordinator: Noha M Sharafeldin, MD,MSc, PhD
- Email: nsharaf@uab.edu
- Phone: 2056382144
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.